OR WAIT null SECS
SeraNovo and Carna Biosciences have announced a second license agreement that will expand the existing partnership to include joint development of an oral formulation of Carna’s kinase inhibitor.
Formulation company, SeraNovo, and biopharmaceutical company, Carna Biosciences, have announced a second license agreement that will expand the existing partnership to include joint development of an oral formulation of Carna’s kinase inhibitor.
According to a May 26, 2020 press release, the terms of the secondary license agreement will see SeraNovo use its Deep Eutectic Solvent (DES) formulation platform to increase the oral bioavailability of one of Carna’s proprietary drugs. The formulation platform from SeraNovo is based on generally recognized as safe (GRAS) excipients that are widely used within the industry for oral administration.
“After our initial license announcement in October 2019, we are pleased to extend our relationship with Carna to include the formulation of another promising active ingredient,” said Niall Hodgins, CEO of SeraNovo in the press release. “This expansion of our partnership with an industry leader is a great development towards wide-spread adoption of our breakthrough formulation technology.”